<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We investigated the effect of a novel <z:chebi fb="0" ids="36621">quinazoline</z:chebi> derivative (KB-5666), a <z:chebi fb="23" ids="18059">lipid</z:chebi> peroxidation inhibitor, on ischemic neuronal damage using Mongolian gerbils </plain></SENT>
<SENT sid="1" pm="."><plain>The animals were sacrificed 7 or 30 days after 5 min of forebrain <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> induced by bilateral common carotid <z:mp ids='MP_0006134'>artery occlusion</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>Morphologic changes, a microtubule-associated protein 2 (MAP2) immunohistochemical study and quantitative autoradiographic study using [3H]<z:chebi fb="0" ids="8116">phorbol</z:chebi> 12, 13-dibutyrate ([3H]<z:chebi fb="0" ids="17598">PDBu</z:chebi>) were evaluated in the hippocampus after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>KB-5666 (3-50 mg/kg, i.v.) showed protective effects against neuronal <z:hpo ids='HP_0011420'>death</z:hpo> of the CA1 subfield 5 min before <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, immediately or 1 hr after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, but not 4 hr after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>KB-5666 (i.p.) also showed protective effects in a dose-dependent manner immediately after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Furthermore, KB-5666 dose-dependently prevented a marked decrease in microtubule-associated protein 2 immunoreactivity in the dendritic fields of the CA1 pyramidal cells after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>The [3H]<z:chebi fb="0" ids="17598">PDBu</z:chebi> binding activity in the stratum oriens and the stratum lacunosum-moleculare of the CA1 subfield was reduced by 19 and 30%, respectively, 7 days after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>[3H]<z:chebi fb="0" ids="17598">PDBu</z:chebi> binding sites were unchanged in the stratum oriens in the CA3 subfield </plain></SENT>
<SENT sid="8" pm="."><plain>By contrast, in the molecular layer of the dentate gyrus, the [3H]<z:chebi fb="0" ids="17598">PDBu</z:chebi> binding activity increased by 15% </plain></SENT>
<SENT sid="9" pm="."><plain>KB-5666 (i.v.) prevented a decrease in the [3H]<z:chebi fb="0" ids="17598">PDBu</z:chebi> binding activity in the stratum oriens and stratum lacunosum-moleculare of the CA1 subfield and an increase in the molecular layer of the dentate gyrus </plain></SENT>
<SENT sid="10" pm="."><plain>These histologic, immunohistochemical and receptor-autoradiographic data indicate that KB-5666 protects the brain from both cellular and functional consequences of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
</text></document>